Skip to content

Author

Akash Virupakshaiah

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Clinical Characteristics and Visual Outcomes of Optic Neuritis in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

BACKGROUND Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a neuro-immunological disorder that can cause optic neuritis (ON) and significant visual impairment. Our objective was to investigate clinical characteristics and visual outcomes in children with MOGAD-ON. METHODS Retrospective coho...

Takhmina Abdul, Arina Nisanova, Anjalee Chopra et al. · 0 citations
Open access Aug 2026

Acute Attack Treatment Escalation and Subsequent Relapse Risk in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Objectives Acute treatment for myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) includes high-dose IV methylprednisolone (IVMP), with escalation to IV immunoglobulin (IVIG) and/or plasma exchange (PLEX) based on severity or incomplete response. We evaluated whether escalation at first attack infl...

Silvia Bartolomeo, Riccardo Nistri, N. Kim et al. · 0 citations
#diffusion models Open access Nov 2026

Reduced Paramagnetic Rim Visibility Signals Lesion Aging and Tissue Degeneration in Progressive Multiple Sclerosis: Impact on Clinical Trials.

Underlying tissue destruction in Definite vs Probable PRLs in people with progressive MS is assessed using quantitative MRI to assess underlying tissue destruction in PRLs in people with progressive MS.

S. Sacco, Hao-Jun Zhao, Shui-Ting Cheng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.